First published in The Pharma Letter on October 20, 2025

From skeptic to builder: why I changed my mind about AI for biology

By: Albi Celaj, Head of ML Research, Deep Genomics

In 2014, I sat in a room at a “Genetic Networks” conference listening ...

Thong Q. Le and Paul Sekhri Join Board of Directors at Deep Genomics

Deep Genomics, the AI-first TechBio organization pioneering a new path for genomic medicines with its AI foundation model platform, today announced the appointment of respected business leaders Thong Q. Le and Paul ...

First published on Pharmaphorum on August 14, 2025

The TechBio way: Brendan Frey talks genomics, AI, and RNA

Overall, the pharmaceutical industry is moving away from an approach where AI is task-driven, narrowly focused on a single, isolated problem. Instead, companies are embracing foundation models ...

First published in STAT+ on June 18, 2025

Why AI for drug discovery will far exceed current expectations 

The usual biotech metric of “how many AI drugs are in the clinic?” misses the point

By Brendan Frey, Chief Innovation Officer and Co-founder of Deep Genomics ...

Biotech Leaders Guide Next Phase of Innovation and Growth for Deep Genomics as Members of Scientific Advisory Board

Deep Genomics, the AI-first TechBio organization pioneering a new path for genomic R&D with its AI foundation model platform, have added two highly respected scientific leaders to ...

Deep Genomics Expands AI Foundation Model Platform for Decoding RNA Biology

Deep Genomics, the AI-first TechBio organization pioneering a new path for genomic R&D, today announced the latest addition to its foundation model platform. The new deep learning model, REPRESS, accurately predicts microRNA (miRNA) binding ...

First published on MedCity News on September 4, 2024

RNA Foundation Models to Improve Pharma R&D Productivity

As RNA biology and RNA therapeutics emerge in the mainstream of pharma, RNA foundation models offer massive potential for revolutionizing R&D.

By Brendan Frey, Chief Innovation Officer and ...

First published on Medicine Maker on August 27, 2024

Why Pharma Must Embrace AI and Open Source

With open minds and open sources, the future is foundational – and bright.

By Brendan Frey, Chief Innovation Officer and Co-founder of Deep Genomics 

The cost of bringing new ...